Novartis' Rasilez lowers blood pressure over 1 year
This is because many patients are prescribed only one medication when a combination of drugs is often needed to reach targets, Nathwani said. Treatment is also hampered by the fact that patients often forget or otherwise fail to take their medications because the disease doesn't have symptoms that are apparent on a day-to-day basis. This is why it's important that the blood pressure of patients who have been taking Rasilez rises only slowly after they stop, Nathwani said. „A lot of the time, people are not taking their medication and when they forget, you don't want blood pressure to go back to what it was or even higher and you also want to make sure they're still protected,” he said. „This is a chronic disease and if you lose control every time the patient forgets a pill, there are going to be important long-term consequences.” The study, led by Domenic Sica, a researcher at Virginia Commonwealth University in Richmond, Virginia, looked at 1,625 patients taking either 150 milligram or 300 milligram doses of the medicine, which is also known as aliskiren. The data is being released at the conference in Barcelona.
Blood pressure readings are given as two numbers. The first, known as the systolic blood pressure reading, represents the maximum pressure exerted when the heart contracts. The second, the diastolic blood pressure reading, represents the pressure in the arteries when the heart is at rest. The reading is given in units of millimeters of mercury, or mmHg. Measurements below 120/80 are considered normal, according to the National Institutes of Health in the US Doctors generally treat patients who have systolic blood pressure higher than 140, Nathwani said. Patients taking the highest dose of the medicine had a drop in systolic blood pressure of 18.8 mmHg on average and a drop in diastolic blood pressure of 13.3 mmHg.
The study also looked at the effect of stopping treatment by switching some patients to a placebo after 11 months. Patients taking the medicine during this „withdrawal period” maintained the reduction in blood pressure. A „gradual” rise in blood pressure was seen in those who started taking the placebo instead, the study said. Novartis' Nathwani said the company is seeking approval for the medicine to be used both alone and in combination with other drugs. Rasilez will likely be used as part of a combination and sales are likely to rise only gradually at first, he said. „Doctors go for those medicines that they've had experience with first,” he said. „It'll be the same in this case. If the other medicines don't work, then they'll try Rasilez.” He reiterated that the company expects the medicine to generate more than $1 billion in peak sales. (Bloomberg)
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.